Remove DEA Remove Decriminalization Remove Patients Remove Treatment
article thumbnail

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Veriheal

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access. A Push by Patients.

Therapy 55
article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. View original article.

DEA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Published Via JD Supra. The state of the law on psychedelic substances is in flux.

Law 105
article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. 7] And cities around the country are beginning to decriminalize some psychedelics, with advocates for decriminalization citing the potential medical benefits. DEA and the Controlled Substances Act. Defining Psychedelics.

article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Background.

DEA 52
article thumbnail

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.

Therapy 89
article thumbnail

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.